Association between adalimumab dosing interval and uveitis recurrence in patients with ankylosing spondylitis
Biomedicines 2025;13:2089 Doi: 10.3390/biomedicines13092089
This study by Lee et al. is the first to evaluate the association between adalimumab dosing intervals and uveitis recurrence in patients with AS. Authors investigated whether extending the dosing interval of adalimumab influences the recurrence of uveitis in AS patients with a history of AU who are on adalimumab therapy.